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Clonal hematopoiesis of indeterminate potential (CHIP) increases with age and is associated
with increased risks of hematological malignancies. While TP53 mutations have been iden-
tified in CHIP, the molecular mechanisms by which mutant p53 promotes hematopoietic
stem and progenitor cell (HSPC) expansion are largely unknown. Here we discover that
mutant p53 confers a competitive advantage to HSPCs following transplantation and pro-
motes HSPC expansion after radiation-induced stress. Mechanistically, mutant p53 interacts
with EZH2 and enhances its association with the chromatin, thereby increasing the levels of
H3K27me3 in genes regulating HSPC self-renewal and differentiation. Furthermore, genetic
and pharmacological inhibition of EZH2 decreases the repopulating potential of p53 mutant
HSPCs. Thus, we uncover an epigenetic mechanism by which mutant p53 drives clonal
hematopoiesis. Our work will likely establish epigenetic regulator EZH2 as a novel therapeutic
target for preventing CHIP progression and treating hematological malignancies with TP53
mutations.
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C lonal hematopoiesis of indeterminate potential (CHIP),also known as age-related clonal hematopoiesis (ARCH),occurs when a single mutant hematopoietic stem and
progenitor cell (HSPC) contributes to a significant clonal pro-
portion of mature blood lineages during aging1–3. CHIP is
common in aged healthy individuals and associated with
increased risks of hematological neoplasms, including myelo-
dysplastic syndromes (MDS) and acute myeloid leukemia
(AML)4–8. CHIP is also associated with increased all-cause
mortality and risk of cardio-metabolic disease4–6,9. While these
findings suggest that mutations identified in CHIP likely drive
disease development, mechanisms by which these mutations
promote HSPC expansion are largely unknown4–9.
Most individuals with CHIP carry hematological malignancy-
associated mutations, including DNMT3A, TET2, ASXL1, JAK2,
and TP534–6. The TP53 gene, which encodes the tumor sup-
pressor protein p53, ranks in the top five among genes that were
mutated in CHIP4–6,10–12. p53 bears the usual hallmarks of a
transcription factor and regulates a large number of genes in
response to a variety of cellular insults, including oncogene
activation, DNA damage, and inflammation, to suppress tumor-
igenesis13,14. TP53 mutations and deletions were found in
approximately half of all human cancers, including hematological
malignancies13,14. Recently, somatic TP53 mutations were iden-
tified in CHIP4–6. TP53 mutations were also commonly found in
therapy-related CHIP10,12. Interestingly, some individuals with
Li-Fraumeni syndrome (LFS), who carry germline TP53 muta-
tions, develop MDS and AML as they age14,15. Indeed, somatic
TP53 mutations are present in 10% of MDS and AML cases and
in 30% of secondary MDS and AML patients arising after
exposure to radiation or chemotherapy2,16–19. While TP53
mutations are associated with adverse clinical outcomes in MDS
and AML2,16–19, how mutant p53 drives the pathogenesis of
hematological malignancies are not fully understood.
We have been investigating the role of p53 in normal and
malignant hematopoiesis. We discovered that wild-type (WT)
p53 maintains hematopoietic stem cell (HSC) quiescence and
identified Necdin as a p53 target gene that regulates DNA damage
response (DDR) in HSCs20,21. We extended our research to
mutant p53 to generate additional knowledge in order to develop
therapeutic strategies that can enhance our abilities to prevent
CHIP progression and treat hematological diseases. We dis-
covered that mutant p53 enhances the repopulating potential of
HSPCs22. While clinical studies suggest that expansion of HSPCs
with TP53 mutations predisposes the elderly to hematological
neoplasms4–6,10–12, the role of TP53 mutations in CHIP pro-
gression remains elusive.
Polycomb group (PcG) proteins are epigenetic regulators that
have been implicated in stem cell maintenance and cancer
development23–26. Genetic and biochemical studies indicate that
PcG proteins exist in at least two protein complexes, Polycomb
repressive complex 2 (PRC2) and Polycomb repressive complex 1
(PRC1), that act in concert to initiate and maintain stable gene
repression23–26. EZH2, a key component of PRC2 complex, cat-
alyzes the trimethylation of lysine 27 of histone H3 (H3K27me3)
in cells25. While EZH2 plays important roles in HSCs and MDS
development16,27,28, its regulation in HSPCs is not fully
understood.
In the present study, we discovered that mutant p53 confers a
competitive advantage to HSPCs following transplantation and
promotes HSPC expansion after radiation-induced stress.
Mechanistically, mutant p53 interacts with EZH2 and enhances
its association with the chromatin, thereby increasing the levels of
H3K27me3 in genes regulating HSPC self-renewal and differ-
entiation. Thus, we have uncovered an epigenetic mechanism by
which mutant p53 drives clonal hematopoiesis.
Results
TP53 mutations identified in CHIP enhance HSPC functions.
TP53 ranks in the top five among genes that were mutated in
CHIP (Fig. 1a)4–6,10–12. Approximately 90% of somatic TP53
mutations in CHIP are missense mutations in the DNA-binding
domain (DBD) of the p53 protein (Fig. 1b)4–6,10–12. The most
frequently mutated codon in p53 was 248, followed by codons
273, 220, and 175 (Fig. 1c). TP53 mutation spectrums in CHIP
are similar to hematological malignancies. Different mutant p53
proteins have been shown to exhibit distinct functions in pro-
moting cancer initiation, progression, or metastasis14. To deter-
mine the impact of TP53 mutations on HSPC functions, we
introduced eight hot-spot TP53 mutations identified in
CHIP4–6,10–12 (Fig. 1c), into WT mouse HSPCs using retrovirus-
mediated transduction and performed in vitro and in vivo assays
(Fig. 1d). Ectopic expression of some mutant p53, including
p53R248W, p53R248Q, p53R175H, p53R273H, p53C238Y, and
p53Y220C, enhanced the replating potential of WT HSPCs com-
pared to control viruses (MIGR1) transduced cells (Fig. 1e).
p53R248W, p53R273H, and p53Y220C are hot-spot TP53
mutations in CHIP, MDS, and AML and predict leukemia
development4–6,10–12,17–19. These mutations have also been
shown to gain oncogenic properties in mouse models of human
cancer14,29–31. We introduced p53R248W, p53R273H, or p53Y220C
into WT HSPCs (CD45.2+) using retrovirus-mediated transduc-
tion, and then transplanted transduced cells (GFP+) together
with competitor bone marrow (BM) cells (CD45.1+) into lethally
irradiated recipient mice. We observed increased number of
GFP+ cells in peripheral blood (PB) of recipient mice repopulated
with HSPCs expressing mutant p53 compared to that of control
viruses transduced cells at 16 weeks following transplantation
(Fig. 1f). Increases in total GFP+ cells in PB at 16 weeks from
mice with mutant p53 proteins were highly suggestive of
enhanced HSPC repopulating potential.
p53 is important for HSC survival following genotoxic stress
and p53 null HSCs are less sensitive to irradiation as manifested
by decreased apoptosis20. We found that ectopic expression of
p53R248W, p53R273H, or p53Y220C in WT HSPCs resulted in
decreased apoptosis following 2 Gy irradiation (Fig. 1g), suggest-
ing that HSPCs expressing these mutant p53 proteins are not
sensitive to radiation-induced stress.
TP53 mutations in CHIP confer competitive advantage to
HSPCs. Given that codon 248 of the p53 protein (p53R248) is
most frequently mutated in CHIP, MDS, and AML4,6,10–12,18,19,
we focused our investigation on p53R248W in hematopoiesis.
Since overexpression of mutant p53 from an MSCV promoter
may not reflect accurate function when expressed at physiological
levels, we utilized the p53R248W knock-in mice, where p53R248W
was introduced into the humanized p53 knock-in (HUPKI) allele
in mice, expressing human p53 mutant protein from the endo-
genous murine Trp53 promoter31. The HUPKI allele encodes a
human/mouse chimeric protein consisting primarily of human
p53 sequence (amino acids 33–332) flanked by the conserved
extreme amino and carboxyl-termini of mouse p5332. HUPKI
mice were described as p53+/+ mice in the text.
Since the majority of TP53 mutations in CHIP are mono-allele
missense mutations (Fig. 1b)4–6,10–12, we utilized heterozygous
mutant mice (p53R248W/+) to investigate the biological impact of
mutant p53 on primitive HSPC populations. As nonsense,
frameshift, and splice site mutations result in TP53 deletions14,
we also included p53+/− and p53−/−mice in the experiments. We
first analyzed the BM of p53+/+, p53+/−, p53−/−, and p53R248W/+
mice and found that BM cellularity is comparable among these
mice (Supplementary Fig. 1a). We observed increased number of
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LSKs and LT-HSCs in the BM of p53−/− mice as reported20;
however, p53R248W affects neither the frequency nor the number
of HSPCs in the BM (Fig. 2a, b, and Supplementary Fig. 1b, c).
While loss of p53 decreases the quiescence of LSKs and LT-
HSCs20, mutant p53 does not affect HSPC quiescence (Fig. 2c, d).
In addition, we observed similar number of apoptotic HSPCs in
p53+/+, p53+/−, p53−/−, and p53R248W/+ mice in steady state
(Fig. 2e). Thus, mutant p53 does not affect the frequency,
quiescence, or the survival of HSPCs when expressed at
physiological levels.
Hematopoietic transplantation is a cellular stressor that has
been shown to promote the expansion of mutant HSPCs12,33,34.
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Fig. 1 TP53 mutations identified in CHIP enhance HSPC repopulating potential. a Tumor suppressor gene TP53 ranks in the top five among genes that
were mutated in clonal hematopoiesis with indeterminate potential (CHIP). b Pie chart representing different types of TP53 mutations identified in CHIP.
c TP53 mutations in CHIP are enriched in the DNA-binding domain (DBD) of the p53 protein. TAD, transactivation domain; PRD, proline-rich domain; DBD,
DNA-binding domain; TET, tetramerization domain; and REG, carboxy-terminal regulatory domain. d Several hot-spot TP53 mutations identified in CHIP
were introduced into wild-type hematopoietic stem and progenitor cells (HSPCs) using retrovirus-mediated transduction. In vitro and in vivo stem and
progenitor cell assays were then performed using sorted GFP (green fluorescent protein)-postive cells. e Serial replating assays of HSPCs expressing
different mutant p53 proteins. The methylcellulose cultures were serially replated, weekly, for 3 weeks; n= 3 independent experiments performed in
duplicate. f Percentage of GFP+ cells in the peripheral blood (PB) of recipient mice following competitive transplantation; n= 3–5 mice per group. g HSPCs
expressing mutant p53 proteins were assessed for apoptosis at 24 h after radiation (2 Gy); n= 3 independent experiments. Data are represented as
mean ± SEM. P-values were calculated using two-way ANOVA (analysis of variance) with Dunnett’s multiple comparisons test in e and f, one-way ANOVA
with Dunnett’s multiple comparisons test in g; *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001. Source data are provided as a Source Data file.
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We recently reported that p53R248W enhances the repopulating
potential of BM cells22. To further establish that the enhanced
repopulating potential is HSC intrinsic, we purified HSCs
(CD48−CD150+LSKs, CD45.2+) from p53+/+, p53+/−, p53−/−,
and p53R248W/+ mice and performed HSC transplantation assays.
Both p53−/− and p53R248W/+ HSCs exhibited a substantially
higher contribution to PB production compared to p53+/+ and
p53+/− HSCs at 20 weeks following primary transplantation
(Fig. 2f). In addition, the percentage of donor-derived hemato-
poietic cells and HSPCs in the BM of recipient mice repopulated
with p53−/− and p53R248W/+ HSCs was significantly higher than
that of the p53+/+ HSCs (Fig. 2g, h). Mutant p53 did not affect
myeloid and lymphoid differentiation in PB and the BM of
recipient mice following HSC transplantation (Supplementary
Fig. 1d, e).
To determine the impact of mutant p53 on HSC self-renewal,
we performed secondary BM transplantation assays. We found
that both p53−/− and p53R248W/+ HSCs continue to show
enhanced engraftment compared to p53+/+ and p53+/− HSCs at
20 weeks following secondary transplantation. Interestingly,
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p53+/− HSCs show increased repopulating potential compared to
p53+/+ HSCs in secondary transplantation assays (Supplemen-
tary Fig. 1f). We observed increased number of donor-derived
hematopoietic cells in the BM of secondary recipients repopulated
with p53+/−, p53−/−, and p53R248W/+ cells compared to p53+/+
cells (Supplementary Fig. 1g). However, neither TP53 mutation
nor p53-deficiency alters terminal differentiation of HSCs
(Supplementary Fig. 1h).
To enumerate the numbers of functional HSCs in the BM of
p53R248W/+ mice, we performed competitive BM transplantation
experiments with limiting-dilution of donor cells. The frequency
of competitive repopulation units (CRU) in the BM of
p53R248W/+ mice is three- to four-fold higher than that of the
p53+/+ mice (Fig. 2i, j). Enhanced repopulating potential of
p53R248W/+ BM cells could be due to changes in homing capacities
of donor cells. We performed homing assays but did not detect
difference in the frequency of donor-derived cells in the BM of
recipient mice repopulated with p53R248W/+ BM cells compared to
p53+/+ BM cells (Supplementary Fig. 1i, j). Taken together, we
demonstrate that mutant p53 identified in CHIP confers a
competitive advantage to HSPCs following transplantation.
TP53 mutations promote HSPC survival following radiation.
Therapy-related CHIP in patients with non-hematologic cancers
is common and associated with adverse clinical outcomes10,12.
Cytotoxic therapy results in the expansion of clones carrying
TP53 mutations10,12,35. Indeed, we found that chemotherapy
treatment expands HSPCs expressing mutant p5322. Given that
HSPCs expressing mutant p53 are not sensitive to radiation
(Fig. 1g), we then examined the impact of radiation on mutant
HSPC expansion. We generated mixed BM chimeras containing
both p53R248W/+ (CD45.2+) and p53+/+ (CD45.1+) cells with a
1:10 ratio of mutant to WT cells. Eight weeks following trans-
plantation, recipient mice were treated with or without 5 Gy total
body irradiation (TBI) (Fig. 3a). We found that mutant BM cells
outcompeted p53+/+ cells, and became clonally dominant
following TBI (Fig. 3b). Further, TBI significantly increased fre-
quency of mutant HSPCs in BM of recipient mice (Fig. 3c, d).
Thus, we demonstrate that radiation promotes the expansion of
HSPCs with mutant p53.
To determine the impact of radiation on p53+/+ and p53R248W/+
mice, we irradiated these mice and monitored their survival. While
most p53+/+ mice died 5 weeks following 9 Gy TBI, most
p53R248W/+ mice were still alive (Supplementary Fig. 2a). Further,
p53R248W/+ HSCs show decreased apoptosis both in vitro and
in vivo following 2 Gy irradiation (Fig. 3e, f). Using phosphoryla-
tion of histone H2AX (γH2AX) as an indicator of DNA damage,
we found that p53+/+ HSCs stained positive for γH2AX, whereas
p53R248W/+ HSCs were largely devoid of γH2AX foci (Supple-
mentary Fig. 2b, c).
To determine the impact of radiation on p53R248W/+ HSPC
function in vivo, we treated p53+/+ and p53R248W/+ mice with 2
Gy TBI. Two hours following TBI, we isolated live BM cells from
irradiated mice and performed competitive transplantation
assays. Irradiated mutant BM cells displayed enhanced repopulat-
ing potential in primary transplantation assays compared to
irradiated WT cells (Fig. 3g). We observed increased number of
donor-derived HSPCs in the BM of primary recipient mice
repopulated with live p53R248W/+ BM cells (Fig. 3h and
Supplementary Fig. 2d). Sixteen weeks after secondary transplan-
tation, p53R248W/+ cells continued to show increased repopulat-
ing ability (Fig. 3i). While mutant p53 had no effect on multi-
lineage differentiation in PB of primary recipient mice (Supple-
mentary Fig. 2e), we found decreased myeloid differentiation and
increased B cell differentiation in the PB of secondary recipient
mice repopulated with mutant BM cells (Fig. 3j). Thus, we
demonstrate that TP53 mutations identified in CHIP confer
resistance to radiation, leading to the selective expansion of TP53-
mutant HSPCs.
HSC and AML signatures were enriched in p53 mutant HSPCs.
WT p53 is a transcription factor that activates the transcription of
several target genes in HSCs, including p21 and Necdin20,21.
However, we found that mutant p53 does not alter the expression
of p21 and Necdin in HSCs (Fig. 4a). To understand how mutant
p53 enhances HSPC self-renewal, we performed transcript pro-
filing (using RNA-seq studies and quantitative real-time PCR
(qRT-PCR) analysis) to compare gene expression in HSPCs iso-
lated from p53+/+ and p53R248W/+ mice. We employed Gene Set
Enrichment Assays (GSEA) to group potential mutant p53 target
genes into specific pathways important in HSPC behavior. HSC
and AML signatures were significantly enriched in p53 mutant
HSPCs compared to p53+/+ HSPCs (Supplementary Fig. 3a, b).
Several pathways important for HSC maintenance, including
Regulation of hematopoiesis, Hematopoietic organ development,
Immune response, and Positive regulation of cytokine response,
were significantly enriched in p53R248W/+ HSPCs compared to
p53+/+ HSPCs (Supplementary Fig. 3c). Collectively, the gene
expression profiling data suggest that mutant p53 modulates
specific pathways associated with HSC maintenance and
leukemogenesis.
EZH2 targets were downregulated in p53 mutant HSPCs.
While we found that several hundred genes are either upregulated
or downregulated in p53 mutant HSPCs compared to WT
HSPCs, how mutant p53 regulates gene expression in HSPCs is
Fig. 2 p53R248W/+ confers a competitive advantage to HSPCs. a The frequency of Lin−Sca1+Kit+ cells (LSKs) in the bone marrow (BM) of p53+/+,
p53+/−, p53−/−, and p53R248W/+ mice; n= 7 mice per genotype. b The frequency of long-term hematopoietic stem cells (LT-HSCs) in the BM of p53+/+,
p53+/−, p53−/−, and p53R248W/+ mice; n= 7 mice per genotype. c The quiescence of LSKs was determined by Ki67 and DAPI (4′,6-diamidino-2-
phenylindole) staining followed by flow cytometry analysis; n= 3–7 mice per genotype. d The quiescence of LT-HSCs was determined by Ki67 and DAPI
staining and flow cytometry analysis; n= 3–7 mice per genotype. e The apoptosis of LSKs was determined by Annexin V and DAPI staining and flow
cytometry analysis; n= 5 mice per genotype. f Percentage of donor-derived cells in PB of recipient mice at 20 weeks following HSC transplantation; n= 7
mice per group. g Percentage of donor-derived cells in the BM of recipient mice at 20 weeks following HSC transplantation; n= 7 mice per group.
h Percentage of donor-derived LT-HSCs, short-term hematopoietic stem cells (ST-HSCs), multi-potent progenitors (MPPs), and LSKs in the BM of
recipient mice repopulated with p53+/+, p53+/−, p53−/−, or p53R248W/+ HSCs; n= 7 mice per genotype. iMeasuring the number of functional HSCs in the
BM of p53+/+ and p53R248W/+ mice utilizing limiting dilution transplantation assays. Recipients with <2% donor-derived cells in the peripheral blood were
defined as non-respondent; n= 7–10 mice per group. P= 0.00114. j Poisson statistical analysis of data from Fig. 2i using L-Calc software. Shapes represent
the percentage of negative mice for each dose of cells. Solid lines indicate the best-fit linear model for each dataset. Data are represented as mean ± SEM.
P-values were calculated using one-way ANOVA with Dunnett’s multiple comparisons test in a, b, c, d, e, g, and h, two-way ANOVA with Dunnett’s
multiple comparisons test in f, and χ2 test in i and j; *P < 0.05, **P < 0.01, ***P < 0.001. Source data are provided as a Source Data file.
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unknown. Recent studies revealed that some mutant p53
proteins increase the expression of epigenetic factors, including
MLL1, MLL2, and MOZ (KAT6A), in human cancer cells36.
MLL1 and MLL2 are key components of the MLL complexes
that confer histone H3K4 trimethylation (H3K4me3), which
is an active histone mark important for gene expression37,38.
MOZ is a histone acetyltransferase and mediates histone H3K9
acetylation (H3K9ac)39,40. However, we found that the expression
of MLL1, MLL2, and MOZ is comparable in p53 WT and
mutant HSPCs (Supplementary Fig. 3d), suggesting mutant p53
may utilize other mechanisms to modulate gene expression in
hematopoietic cells.
Interestingly, RNA-seq assays revealed that genes that only
marked by H3K27me3 were negatively enriched with significance
in mutant HSPCs compared to that of the WT HSPCs (Fig. 4b,
left panel). EZH2 target gene signature (without EZH1 compen-
sation) was also negatively enriched with significance in mutant
HSPCs (Fig. 4b, right panel). However, loss of p53 in HSPCs did
not significantly change EZH2 target gene signature (Supple-
mental Fig. 3e). Western blot analysis showed increased levels of
H3K27me3 in p53 mutant HSPCs compared to WT HSPCs
(Fig. 4c). Further, p53R248W/+ HSCs displayed higher levels of
H3K27me3 compared to p53+/+ HSCs quantified by flow
cytometry analysis (Fig. 4d).
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To further understand how mutant p53 modulates gene
expression in hematopoietic cells, we performed H3K27me3
ChIP-seq assays in HSPCs from p53+/+ and p53R248W/+ mice. As
expected, H3K27me3 is enriched at the transcription start site
(TSS). Large regions of H3K27me3 enrichments are also found
covering entire gene regions as well as intragenic regions. We
found that p53 mutant HSPCs exhibited significantly higher
levels of H3K27me3 at TSS compared to that of the WT HSPCs
(Fig. 4e). The heat map of H3K27me3 ChIP-seq also revealed that
many genes show increased H3K27me3 enrichment in mutant
HSPCs compared to that of the WT HSPCs (Fig. 4f). The
majority of H3K27me3 peaks (2582 out of 2669) in WT HSPCs
are overlapped with H3K27me3 peaks in p53 mutant HSPCs
(Supplementary Fig. 4a). By using the same enrichment thresh-
old, we obtained 1232 additional peaks in mutant HSPCs. These
peaks are likely targeted by H3K27me3 in WT cells but failed to
reach the threshold. Indeed, these peaks show a similar pattern of
fold enrichment between mutant and WT HSPCs (Supplemen-
tary Fig. 4b). We also observed increased H3K27me3 enrichment
in other genes in p53 mutant HSPCs (Supplementary Fig. 4c, d).
Increased levels of H3K27me3 were found in genes regulating
HSC self-renewal and differentiation, including Cebpα and
Gadd45g41–43, in p53R248W/+ HSPCs compared to p53+/+ HSPCs
(Fig. 4f, g). The transcription factor C/EBP alpha is required for
granulopoiesis and frequently disrupted in human AML. Loss of
Cebpα enhances HSC repopulating capability and self-
renewal41,42. Tumor suppressor GADD45G induces HSC differ-
entiation following cytokine stimulation, whereas loss of
GADD45G enhances the self-renewal potential of HSCs43. We
confirmed that there were increased levels of H3K27me3 at both
Cebpα and Gadd45g genes by ChIP experiments (Fig. 4h).
Consistently, both Cebpα and Gadd45g were significantly down-
regulated in p53R248W/+ HSCs compared to p53+/+ HSPCs
(Fig. 4i, j).
Stimulation of WT HSPCs with thrombopoietin (TPO)
dramatically increased Gadd45g expression; however, TPO
treatment only modestly increased Gadd45g expression in p53
mutant HSPCs (Supplementary Fig. 5a), suggesting that mutant
p53 may repress Gadd45g expression upon cytokine stimulation.
To determine the impact of Gadd45g on HSPC function in vitro,
we introduced Gadd45g into BM cells from p53+/+ and
p53R248W/+ mice using retroviruses and performed colony
formation as well as transplantation assays. We found that
ectopic Gadd45g expression decreases the colony formation of
p53 mutant BM cells (Supplementary Fig. 5b). Further, ectopic
Gadd45g expression decreased the engraftment of p53 mutant
BM cells in vivo (Supplementary Fig. 5c). Given that loss of
Gadd45g increases HSC self-renewal43, it is possible that
inactivation of Gadd45g is responsible for increased self-
renewal and colony formation seen in p53 mutant HSPCs. We
also found that ectopic Cebpα expression decreases the colony
formation of p53 mutant BM cells (Supplementary Fig. 5d). These
data suggest that mutant p53 may repress gene expression in
HSPCs through increasing the levels of H3K27me3.
Mutant p53 enhances the association of EZH2 with the chro-
matin. The PRC2 complex consists of EZH2/EZH1, EED, and
SUZ1225. While the levels of EZH2 was modestly increased in
mutant HSPCs, the expression of other PRC2 core components
was comparable between p53 WT and mutant HSPCs (Supple-
mentary Fig. 6a). As the protein levels of PRC2 complex in mouse
HSPCs were very low, we determined the impact of mutant p53
on the expression of PRC2 complex in murine hematopoietic
progenitor 32D cells. We found that ectopic expression of mutant
p53, but not WT p53, increased levels of H3K27me3 in 32D cells
(Fig. 5a). However, ectopic expression of neither WT nor mutant
p53 affected the protein levels of PRC2 core components in 32D
cells (Supplementary Fig. 6b). Thus, the increased H3K27me3 in
p53 mutant HSPCs may not be due to increased expression of
catalytic components of PRC2, including EZH2 and EZH1, or
other components of the PRC2 complex.
We then tested whether mutant p53 interacts with EZH2. We
performed co-immunoprecipitation assays and found that several
mutant p53 proteins, including p53R248W, p53R273H, and
p53R175H, displayed enhanced association with EZH2 compared
to WT p53 (Fig. 5b). The recruitment and displacement of the
PRC2 complex on chromatin are a dynamic process and tightly
regulated to activate or repress transcription23–26. Genome-wide
H3K27me3 ChIP-seq assays revealed that the majority of
H3K27me3 peaks in p53 mutant HSPCs are overlapped with
that of the WT HSPCs (Fig. 4e, f, Supplementary Fig. 4a),
suggesting that mutant p53 may enhance the association of EZH2
with the chromatin, thereby increasing the levels of H3K27me3.
To test this, we examine the co-localization of p53 and Ezh2 in
p53 WT and mutant HSPCs utilizing the ImageStream flow
cytometry analysis. The median fluorescent intensity (MFI) of
p53 and Ezh2 in the nucleus was comparable between p53+/+ and
p53R248W/+ HSPCs (Supplementary Fig. 6c, d). However, we
found that mutant p53, but not WT p53, show increased co-
localization with Ezh2 in the nucleus (Fig. 5c, d).
To determine whether mutant p53 enhances the association of
Ezh2 with the chromatin, we separated proteins in p53 WT and
mutant HSPCs into cytosol, nuclear cytosol, and chromatin
bound fractions. While EZH2 was present in the cytosol of both
p53 WT and mutant HSPCs, we observed increased levels of Ezh2
in the chromatin bound faction of p53 mutant HSPCs compared
to that of the p53 WT HSPCs (Fig. 5e). We then performed p53
and EZH2 ChIP assays in p53+/+ and p53R248W/+ HSPCs
Fig. 3 p53R248W/+ confers a survival advantage to HSPCs after radiation. a BM chimeras were generated by transplanting a 1:10 ratio of p53R248W/+
cells (CD45.2+) to p53+/+ cells (CD45.1+) into irradiated recipient mice (CD45.1+CD45.2+). After hematopoietic reconstitution (8 weeks), mice were
treated with or without 5 gray (Gy) total body irradiation (TBI). b Percentage of p53R248W/+ (CD45.2+) cells in PB of recipient mice following TBI
treatment; n= 7 mice per group. c Percentage of p53R248W/+ cells (CD45.2+) in the BM of recipient mice at 16 weeks following TBI treatment; n= 7 mice
per group. d Percentage of p53R248W/+ LSK cells (CD45.2+) in the BM of recipient mice at 16 weeks following TBI treatment; n= 7 mice per group.
e Hematopoietic stem and progenitor cells from p53+/+ and p53R248W/+mice were assessed for apoptosis 2 h after 2 Gy TBI; n= 3 mice per group. f HSCs
purified from the BM of p53+/+ and p53R248W/+ mice were treated with 2 Gy TBI and then assessed for apoptosis; n= 3 mice per group. g Competitive
transplantation assays using BM cells isolated from p53+/+ and p53R248W/+ mice treated with 2 Gy TBI. Two hours following TBI, we isolated BM cells
from irradiated mice and transplanted 500,000 live BM cells together with equal number of competitor BM cells into lethally irradiated recipient mice. The
percentage of donor-derived cells in the PB of recipient mice; n= 7–8 mice per group. h Percentage of donor-derived LT-HSCs, ST-HSCs, MPPs, and LSK
cells in the PB of the primary recipient mice 16 weeks following transplantation; n= 7–8 mice per group. i Contribution of p53+/+ and p53R248W/+ BM cells
to recipient mouse PB in secondary transplantation assays; n= 5–7 mice per group. j Lineage contribution of donor-derived cells in the PB of secondary
recipient mice 16 weeks following transplantation; n= 5–7 mice per group. Data are represented as mean ± SEM. P-values were calculated using two-way
ANOVA with Bonferroni’s multiple comparisons test in b, e, g, i, and j, unpaired t-test with Welch’s correction in c, d, f, and h; *P < 0.05, **P < 0.01,
***P < 0.001, ****P < 0.0001. Source data are provided as a Source Data file.
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(Lin−Kit+ cells) and found that both mutant p53 and EZH2 show
increased association with Cebpα (Supplementary Fig. 6e, f).
Thus, we demonstrate that mutant p53 interacts with EZH2 and
enhances its association with the chromatin, thereby increasing
the levels of H3K27me3 in HSPCs.
Inhibiting EZH2 decreases p53 mutant HSPC expansion.
Hematopoietic-specific deletion of Ezh2 impairs HSC self-renewal
and terminal differentiation28. To determine the functional
impacts of mutant p53 and Ezh2 interaction on hematopoiesis,
we generated p53R248W/+Ezh2f/f-Mx1Cre+ mice28. While Ezh2-
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Fig. 4 EZH2 targets were significantly downregulated in p53 mutant HSPCs. a Quantitative reverse transcription polymerase chain reaction (RT-PCR)
analysis of mRNA levels of p53 target genes, including p21 and Necdin, in HSCs; n= 3 biological replicates. b Gene Set Enrichment Assays (GSEA) analysis
shows that EZH2 targets were significantly downregulated in p53 mutant HSPC compared to p53+/+ HSPCs. c p53 mutant HSPCs display increased levels
of H3K27me3 (trimethylation at lysine 27 of histone H3) determined by immuno-blot analysis. d Lineage depleted HSPCs were stained with SLAM
(signaling lymphocyte activation molecule) surface markers (CD48 and CD150) before fixation. Median fluorescence intensity of H3K27me3 in p53+/+
and p53R248W/+ HSCs (Lin−Sca1+Kit+CD48−CD150+ cells) was detected by ImageStream flow cytometry analysis. p53+/+ n= 35 cells, p53R248W/+
n= 52 cells. e H3K27me3 ChIP-seq (chromatin immunoprecipitation sequencing) tag density in p53+/+ and p53R248W/+ HSPCs, centered on TSS
(transcription start site). f Heat map shows genes in HSPCs marked by H3K27me3. g Genome browser views of H3K27me3 ChIP-seq profiles of Cebpα
(CCAAT/enhancer-binding protein alpha) and Gadd45g (growth arrest and DNA-damage-inducible 45 gamma). h H3K27me3 enrichment on Cebpα and
Gadd45g genes in p53+/+ and p53R248W/+ HSPCs were examined by H3K27me3-ChIP assays; n= 3 independent experiments. i Quantitative RT-PCR
analysis of mRNA levels of Cebpα in p53+/+ and p53R248W/+ LT-HSCs; n= 3 biological replicates. j Quantitative RT-PCR analysis of mRNA levels of
Gadd45g in p53+/+ and p53R248W/+ LT-HSCs; n= 3 biological replicates. Data are represented as mean ± SEM. P-values were calculated using unpaired
t test with Welch’s correction in a and d, paired t-test in h, i, and j, and GSEA software in b; *P < 0.05, ***P < 0.001. Source data are provided as a Source
Data file.
a
e
b
c d
0.0
0.5
1.0
1.5
2.0
2.5
Si
m
ila
rit
y 
sc
or
ep53+/+
p53
Ch02
59,700
10 µm
10 µm
10 µm
10 µm
10 µm
10 µm
57,863
32,972
94,558
88,551
70,727
Ch02
Ch02
Ch02
Ch02
Ch02 Ch03
Ch03
Ch03
Ch03
Ch03
Ch03 Ch02/Ch03
Ch02/Ch03
Ch02/Ch03
Ch02/Ch03
Ch02/Ch03
Ch02/Ch03
Ch07
Ch07
Ch07
Ch07
Ch07
Ch07
EZH2
H3K27me3
WB
HA-EZH2
P53
HA-EZH2:
20 kDa
P53:
Input
32 D
IP: P53
M
IG
R1
p5
3
R
24
8W
+
 
+
 
+
 
+
 
+
 
+
 
+
 
+
 
+
 
+
 
20 kDa
15 kDa
100 kDa
50 kDa
100 kDa
WT R248W
50 kDa
37 kDa
15 kDa
Ezh2
p53
Gapdh
H3
Histones
DAPI Merge
p53R248W/+
p53+/+
WC Cy
tos
ol
NE Ch
rm
WC Cy
tos
ol
NE Ch
rm
p53R248W/+
– –W
T
R
24
8W
R
27
3H
R
17
5H
W
T
R
24
8W
R
27
3H
R
17
5H
Fig. 5 Mutant p53 enhances the association of EZH2 with the chromatin in HSPCs. a 32D cells expressing mutant p53, but not wild-type (WT) p53,
displayed increased levels of H3K27me3 as determined by immuno-blot analysis. b Several mutant p53 proteins, but not wild-type p53, show enhanced
association with EZH2 as assayed by co-IP (co-immunoprecipitation) experiments. cMutant p53 and EZH2 localization in HSPCs (Lin−Sca1+Kit+CD150+)
as determined by ImageStream flow cytometry analysis. d Quantification of p53 and Ezh2 co-localization in the nucleus of HSPCs (Lin−Sca1+Kit+CD150+).
A similarity feature determined the amount of overlay between p53 and Ezh2 within the DAPI mask. The higher the similarity score is, the more co-
localized staining is within the nucleus; n= 3 biological replicates. e Cellular fractionation shows increased EZH2 association with the chromatin fraction in
p53 mutant HSPCs. The absence of Gapdh (glyceraldehyde 3-phosphate dehydrogenase) and exclusive distribution of histone H3 in the chromatin fraction
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deficiency did not affect Cebpα and Gadd45g expression, Ezh2
deficiency brought the expression of Cebpα and Gadd45g back to
normal in the mutant p53 background (Fig. 6a and Supplemen-
tary Fig. 7a).
To determine the impact of genetic inhibition of Ezh2 on p53
mutant HSPC function in vitro, we performed serial replating
assays using BM cells from p53+/+, Ezh2f/+-Mx1Cre+, p53R248W/+,
and p53R248W/+Ezh2f/+-Mx1Cre+ mice following polyinosinic:
polycytidylic acid (pI:pC) treatment. We found that Ezh2-
deficiency brings the replating potential of p53 mutant BM cells
back to the WT cell level (Fig. 6b). To determine the impact of
Ezh2 deficiency on HSPC function in vivo, we performed
competitive BM transplantations. We treated recipient mice with
pI:pC at 8 weeks after transplantation to delete Ezh2 and then
examined donor cell engraftment every 4 weeks for 20 weeks.
p53R248W/+ BM cells exhibited a substantially higher contribution
to PB production compared to p53+/+ cells at 20 weeks following
pI:pC treatment, whereas loss of Ezh2 decreased the engraftment
of mutant BM cells to the WT cell level (Fig. 6c). While both the
frequency and the absolute number of donor-derived HSPCs in
the BM of recipient mice repopulated with p53R248W/+ BM cells
was significantly higher than that of the WT cells, the frequency
and the number of donor-derived HSPCs in the BM of recipient
mice repopulated with p53+/+ and p53R248W/+Ezh2−/− BM cells
were comparable (Fig. 6d, e). In addition, we observed decreased
number of donor-derived CMPs and MEPs in the BM of recipient
mice repopulated with p53R248W/+Ezh2−/− BM cells compared to
that of the p53R248W/+ BM cells (Supplementary Fig. 7b, c),
whereas the number of donor-derived GMPs was comparable in
the BM of recipient mice repopulated with p53R248W/+ cells and
p53R248W/+Ezh2−/− cells (Supplementary Fig. 7d). To determine
the impact of Ezh2-deficiency on mutant HSC self-renewal, we
performed secondary BM transplantation assays and found that
EZH2-deficiency decreases the repopulating potential of
p53R248W/+ HSCs following secondary transplantation assays
(Fig. 6f).
To determine the effect of pharmacological inhibition of
Ezh2 activity on mutant p53 HSPCs, we treated p53+/+ and
p53R248W/+ BM cells with DMSO or EZH2 specific inhibitor
EPZ01198944 and performed serial replating assays. While EZH2
inhibitor had no effect on the colony formation of WT BM cells,
EZH2 inhibitor treatment decreased the replating potential of
p53R248W/+ BM cells to the WT level (Fig. 6g). Thus, we
demonstrate that EZH2 is important for mutant p53 HPSC
functions both in vitro and in vivo.
Discussion
WT p53 is a transcription factor that activates the transcription of
target genes to mediate DNA damage repair, growth arrest, or
apoptosis13,45. Most TP53 mutations observed in human cancers
abrogate or attenuate the binding of p53 to its consensus DNA
sequence (p53 responsive element) and impede transcriptional
activation of p53 target genes14. However, we found that mutant
p53 does not alter the expression of p53 target genes, including
p21 and Necdin, in HSCs (Fig. 4a). Genome-wide transcriptome
assays revealed that HSC and AML signatures are enriched in p53
mutant HSPCs, which is different from gene expression sig-
natures regulated by the WT p53 protein20,45. Thus, our findings
provide experimental evidence that TP53 mutations identified in
CHIP regulate gene expression in a distinct manner compared to
WT p53.
Some mutant p53 proteins have been shown to promote cancer
development through modulating gene transcription14. Dysre-
gulated epigenetic control has been implicated in HSC aging and
the pathogenesis of hematological malignancies16,46–48. RNA-seq
assays revealed that Ezh2 target genes are significantly down-
regulated in p53R248W/+ HSPCs compared to p53+/+ HSPCs. We
observed increased levels of H3K27me3 in p53 mutant HSPCs.
Further, H3K27me3 ChIP-seq assays revealed that p53 mutant
HSPCs exhibit significantly high levels of H3K27me3. Genes
important for HSC self-renewal and differentiation, including
Cebpα and Gadd45g41–43, were occupied with increased levels of
H3K27me3 in p53 mutant HSPCs. Thus, mutant p53 may
enhance HSPC self-renewal through increasing the levels of
H3K27me3 in genes involved in HSC self-renewal and
differentiation.
Then, how does mutant p53 enhances H3K27me3 in HSPCs?
One possible mechanism is that mutant p53 upregulates the
expression of the core PCR2 components, thereby increasing
PRC2 activity. However, the expression of the core PRC2 com-
ponents was comparable between p53 WT and mutant HSPCs.
Mutant p53 is incapable of binding to its normal binding sites
and has been shown to be targeted by interactions with other
transcription factors, including ETS family and SREBP14,36. We
discovered that several mutant p53 proteins show enhanced
association with EZH2 compared to WT p53. H3K27me3 ChIP-
seq assays revealed that the increase in EZH2-dependent
H3K27me3 is broad across genes, pointing toward an alter-
native EZH2/PRC2 targeting strategy or an increase in enzymatic
activity but with normal targeting mechanisms. As shown in
Supplementary Fig. 4a, 96.7% H3K27me3 peaks in WT cells also
show H3K27me3 occupation in p53 mutant cells. Although
additional peaks are enriched in p53 mutant cells, they are indeed
associated with H3K27me3 in WT cells as well albeit lower
enrichment. Further, we found that mutant p53 interacts with
EZH2 and enhances its association with the chromatin in HSPCs.
Thus, mutant p53 appears to enhance H3K27me3 occupation
rather than change its genome-wide distribution in HSPCs.
While the PRC2 complex controls dimethylation and tri-
methylation of H3K27, the Jumonji domain containing-3 (Jmjd3,
KDM6B) and ubiquitously transcribed X-chromosome tetra-
tricopeptide repeat protein (UTX, KDM6A) have been identified
as H3K27 demethylases that catalyze the demethylation of
H3K27me2/349,50. Decreased activity of KDM6A/UTX and
JMJD3 may be an alternative mechanism leading to increased
EZH2 activity. Future studies will be needed to investigate the
potential impact of UTX and JMJD3 on regulating H3K27me3 in
p53 mutant HSPCs.
Most of TP53 mutations in human cancer result in either
partial or complete loss of tumor suppressor function14. Some
mutant p53 proteins acquire new oncogenic properties that are
independent of WT p53, known as the gain-of-function (GOF)
properties14. Most GOF properties are believed to stem from
binding of mutant p53 to cellular proteins such as transcription
factors and altering their activity14. These (neomorphic)
GOF properties can be experimentally demonstrated in the
absence of a functional WT p53. Homozygous p53R248W/R428W
and p53R273H/R273H mice developed novel tumors compared to
p53−/− mice29,31, demonstrating that some mutant p53 proteins
have enhanced oncogenic potential beyond the simple loss of p53
function. WT p53 has not been shown to be associated with
EZH2 activity or H3K27me3. RNA-seq assays revealed that
PRC2-related gene signature was not significantly different
between p53+/+ and p53−/− HSPCs, which is different from what
we observed in p53 mutant HSPCs, suggesting that loss of WT
p53 may affect neither EZH2 activity nor H3K27me3 in HSPCs.
Ectopic expression of mutant p53, but not WT p53, enhances
H3K27me3 in 32D cells. Further, we found that several mutant
p53 proteins show enhanced association with EZH2 compared to
WT p53. While both loss of p53 (p53−/−) and mutant p53
(p53R248W/+) enhances HSC repopulating potential, our data
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suggest that increased levels of H3K27me3 in p53 mutant HSPCs
is likely due to the presence of the mutant allele, but not the result
of losing WT p53 activity. While a dominant-negative (DN) effect
has been shown to drive selection of TP53 missense mutations in
myeloid malignancies51, GOF mutant p53 appears to play an
important role in myeloid leukemia30. Our work suggests that
both DN and GOF properties may contribute to enhanced HSC
self-renewal seen in p53R248W/+ mice.
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Fig. 6 Loss of EZH2 decreases the repopulating potential of p53 mutant HSPCs. a Cebpα expression in p53+/+, Ezh2+/−, p53R248W/+, and p53R248W/+
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Clinical studies revealed that hematopoietic clones harboring
specific mutations in individuals with CHIP may expand over
time4–6. However, how different cellular stressors affect clonal
expansion is largely unknown. Recently, two different stressors,
including hematopoietic transplantation and cytotoxic therapy,
have been shown to expand hematopoietic clones10,12,22,33–35.
We discovered that TP53 mutations identified in CHIP confer a
competitive advantage to HSPCs following transplantation. TP53
mutations are associated with prior exposure to chemother-
apy10,12 and we observed that TP53 mutations confer radiation
resistance, leading to selective expansion of TP53-mutant HSPCs.
Recently, PPM1D mutations were found in CHIP, especially in
patients previously exposed to chemotherapy10,12,33,34. PPM1D is
a phosphatase that negatively regulates p53 and several proteins
involved in the DDR pathway52,53. While PPM1D mutations
result in the expansion of PPM1D-mutant hematopoietic cells
following chemotherapy treatment33,34, they do not confer
competitive advantage to HSPCs following BM transplanta-
tion12,33,34. Thus, p53 and PPM1D appear to play distinct roles in
driving clonal hematopoiesis.
While we have identified a stem cell intrinsic mechanism by
which mutant p53 drives clonal hematopoiesis, recent studies
indicate that mutations identified in CHIP may utilize cell
extrinsic mechanisms to promote clonal hematopoiesis54,55. We
will investigate the cell extrinsic mechanisms by which mutant
p53 drives CHIP in the future. Some individuals with CHIP
developed AML with age2,3. However, the role of mutant p53 in
the initiation and progression of AML is largely unknown18,56.
We recently reported that mutant p53 synergizes with FLT3-ITD
in leukemia development57. We will elucidate the mechanisms by
which mutant p53 drives leukemia development.
In summary, we discovered that TP53 mutations drive clonal
hematopoiesis in response to distinct cellular stressors. Mechan-
istically, mutant p53 interacts with EZH2 and enhances its
association with the chromatin, increasing the levels of
H3K27me3 in genes regulating HSPC self-renewal and differ-
entiation. EZH2 is rarely mutated in CHIP4–6 and we found that
genetic and pharmacological inhibition of EZH2 decrease the
repopulating potential of p53 mutant HSPCs. Thus, our work will
likely establish epigenetic regulator EZH2 as a novel therapeutic
target for preventing CHIP progression and treating hematolo-
gical malignancies with TP53 mutations.
Methods
Mice. The HUPKI (p53+/+) and p53R248W/+ mice used in our studies have been
backcrossed to the C57BL6 background for 12 generations22,31. All young p53+/+,
p53+/−, p53−/−, and p53R248W/+ and Ezh2F/F-Mx1-Cre+ mice used in these
studies are 8–12 weeks old and are tumor free. WT C57BL/6 (CD45.2+), B6.SJL
(CD45.1+), and F1 mice (CD45.2+ CD45.1+) mice were obtained from an on-site
core breeding colony. We have complied with all relevant ethical regulations for
animal testing and research. All animal-related experiments have received ethical
approval from the Indiana University Institutional Animal Care and Use Com-
mittee (IACUC). All mice were maintained in the Indiana University Animal
Facility according to IACUC-approved protocols.
Generation of retroviruses and infection of HSPCs. Retroviral vectors were
produced by transfection of Phoenix E cells with the MIGR1 control or MIGR1
full-length mutant p53 cDNA plasmids, according to standard protocols. Mouse
HSPCs were infected with high-titer retroviral suspensions in the presence of
Retronectin. Forty-eight hours after infection, the GFP-positive cells were sorted by
FACS20,21.
Stem and progenitor cell assays. Clonogenic progenitors were determined in
methylcellulose medium (MethoCult GF M3234, StemCell Technologies) using 2 ×
104 BM cells per well (6-well plate). Colonies were scored after 7 days of the initial
culture, and all cells were collected and washed twice in PBS. Subsequently cells
were cultured in the same medium. Colony scoring and replating were repeated
every 7 days for at least two times20,21.
Flow cytometry. Murine HSPCs were identified and evaluated by flow cytometry
using a single cell suspension of bone marrow mononuclear cells (BMMCs).
Hematopoietic stem and progenitors are purified based upon the expression of
surface markers: LT-HSC (Lin−Sca1+Kit+CD48−CD150+), ST-HSC
(Lin−Sca1+Kit+CD48−CD150−), MPP (Lin−Sca1+Kit+CD48+CD150−),
CMP (Lin−Sca1−Kit+CD16/32wlowCD34high), GMP (Lin−Sca1−Kit+CD16/
32whighCD34high), and MEP (Lin−Sca1−Kit+CD16/32wlowCD34low). BM cells
were obtained from tibia, femur, and iliac crest (6 from each mice) by flushing cells
out of the bone using a syringe and phosphate-buffered saline (PBS) with 2 mM
EDTA. Red blood cells (RBCs) were lysed by RBC lysis buffer (eBioscience) prior to
staining. Experiments were performed on FACS LSR IV cytometers (BD Bios-
ciences) and analyzed by using the FlowJo software (TreeStar).
Ki-67 staining. BM cells were stained for cell surface markers as described above.
After staining, cells were washed with 0.2% BSA in PBS, fixed and permeabilized
using Cytofix/Cytoperm buffer (BD Biosciences) and then incubated with PE-
conjugated-antibody against Ki-67 (BD Biosciences) for more than 30 min on ice.
Cells were washed, incubated with 4′,6-diamidino-2-phenylindole (DAPI) (Sigma)
and acquired using LSR IV flow cytometer machine20,21. Data analysis was per-
formed using FlowJo software.
Hematopoietic cell transplantation. For HSC transplantation, we injected 200
CD48−CD150+LSK cells from p53+/+, p53+/−, p53−/−, and p53R248W/+ mice
(CD45.2+) plus 3 × 105 competitor BM cells (CD45.1+) into lethally irradiated F1
mice (CD45.1+CD45.2+). The percentage of donor-derived (CD45.2+) cells in PB
was analyzed every 4 weeks after transplantation as described above. Twenty weeks
following transplantation, we harvested BM cells from recipient mice and performed
flow cytometry analysis to evaluate HSC repopulating capability. For secondary
transplantation assays, 3 × 106 BM cells from mice repopulated with p53+/+, p53+/−,
p53−/−, and p53R248W/+ HSCs were transplanted into lethally irradiated F1 mice.
For the competitive BM repopulation assays, we injected 5 × 105 BM cells from
p53+/+ and p53R248W/+mice (CD45.2+) plus 5 × 105 competitor BM cells (CD45.1+)
into 9.5 Gy lethally irradiated F1 mice (CD45.1+CD45.2+). PB was obtained by tail
vein bleeding every 4 weeks after transplantation, RBC lysed, and the PB mononuclear
cells stained with anti-CD45.2 FITC and anti-CD45.1 PE, and analyzed by flow
cytometry. Sixteen weeks following transplantation, BM cells from recipient mice
were analyzed to evaluate donor chimerisms in BMs. For secondary transplantation,
3 × 106 BM cells from mice reconstituted with p53+/+ or p53R248W/+ BM cells were
injected into 9.5 Gy lethally irradiated F1 mice (CD45.1+CD45.2+).
Limiting dilution assays. Different doses (10,000, 20,000, 40,000, 80,000) of BM
cells from p53+/+ and p53R248W/+ mice (CD45.2+) together with 200,000 com-
petitor cells (CD45.1+) were transplanted into lethally irradiated (9.5 Gy) F1
recipient mice (CD45.2+CD45.1+). The percentage of donor-derived (CD45.2+)
cells were analyzed 16-weeks following transplantation as described above. HSC
frequency was calculated using L-Calc software (StemCell Technologies Inc.) and
ELDA software (bioinf.wehi.edu.au/software/elda/). Poisson statistics was used to
calculate the P value.
Homing assays. A total of 1 × 107 p53+/+ and p53R248W/+ BM cells (CD45.2+)
were injected into lethally irradiated recipient mice (CD45.1+). BM cells were
harvested 18 h following injection and the frequency of donor-derived cells
(CD45.2+) was evaluated by flow cytometry.
Quantitative real-time PCR. Total RNA was extracted from cells using RNeasy
Plus Micro Kit (Qiagen) and cDNA was prepared from total RNA using Super-
Script IV First-Strand cDNA Synthesis Kit (Invitrogen Life Technologies) and oligo
(dT) primers, following manufacturer’s instructions. qRT-PCR assay was per-
formed by using the 7500 Real Time PCR machine (Applied Biosystems) with
FastStart Universal SYBR Green Master (ROX) (Roche).
ImageStream flow cytometry analysis. To quantify γ-H2Ax foci in HSPCs,
lineage-depleted BM cells were first stained with antibodies against appropriate
HSPC surface markers, then fixed and permeabilized using the Cytofix/Cytoperm
Kit (BD Biosciences), as described by the manufacturer, and finally stained with an
Alexa-488-conjugated anti-γ-H2Ax antibody (Cell Signaling Technology).
To quantify the intensity of H3K27me3 in HSPCs, lineage-depleted BM cells
were first stained with antibodies against HSPC surface markers, then fixed and
permeabilized using the Cytofix/Cytoperm Kit (BD Biosciences), as described by the
manufacturer, and finally stained with an Alexa-488-conjugated anti-H3K27me3.
For quantitative image analysis of p53 and Ezh2 co-localization within the
nucleus, fluorescent cell images (×40) were acquired using an ImageStream flow
cytometry system (Amnis; Seattle, WA, http://www.amnis.com). Between 171 and
554 Lin−Sca1+cKit+CD150+ cell images were analyzed per sample using IDEAS
software (Amnis; Seattle, WA, http://www.amnis.com). In focus cells were evaluated
after gating on live, single, Lin−Sca1+cKit+CD150+ cells. Utilizing DAPI staining,
we were able to create a nucleus mask and instruct the program to only look at the
staining of p53 and Ezh2 within the DAPI/nucleus mask. Bright detail intensity of
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FITC‐p53, PE‐Ezh2, and DAPI staining was used to quantify mean and geo mean
intensity and co-localization within the nucleus. A similarity feature determined the
amount of overlay between p53 and Ezh2 within the DAPI mask. The higher the
similarity score is, the more co-localized the staining within the nucleus.
Co-IP. H1299 cells (p53 null) were co-transfected with FLAG-HA-EZH2 and WT or
mutant p53, respectively, or transfected with FLAG-HA-EZH2 alone. Nuclear extract
(NE) was prepared from these cells and incubated with a polyclonal p53 antibody
(FL393, Santa Cruz) prior to addition of protein G beads. After overnight incubation,
beads were then washed five times and eluted with glycine (0.1M, pH 2.0), and then
neutralized by adding Tris solution (1.5M, pH 8.8). The eluates were mixed with
SDS sample buffer and analyzed by SDS-PAGE, followed by immunoblotting58.
Cellular fractionation. Briefly, p53+/+ and p53R248W/+ HSPCs were harvested and
lysed in Buffer A (10 mM Tris-HCl, pH 7.9, 1.5 mM MgCl2, 10 mM KCl, 0.5 mM
DTT, 0.2 mM PMSF, 1 μg/ml pepstatin A, 1 μg/ml leupeptin, 1 μg/ml aprotinin).
The cell lysate was then homogenized by a dounce homogenizer for 10 strokes and
centrifuged at 4 °C and 15,000×g for 10 min. The supernatant was saved as the
cytosolic fraction. The pellet was washed with Buffer A and then re-suspended with
Buffer C (20 mM Tris-HCl, pH 7.9, 25% glycerol, 420 mM NaCl, 1.5 mM MgCl2,
0.2 mM EDTA, 0.5 mM DTT, 0.2 mM PMSF, 1 μg/ml pepstatin A, 1 μg/ml leu-
peptin, 1 μg/ml aprotinin) and dounced for 10 strokes. Suspension was rotated at
4 °C for 30 min and centrifuged at 4 °C and 7500×g for 5 min. The supernatant was
saved as the nucleoplasmic fraction. The pellet was saved as the chromatin fraction
and re-suspended with Buffer C. Cell fractions were mixed with SDS sample buffer
and heated at 95 °C for 5 min59. Whole-cell extraction, nucleoplasmic, and chro-
matin extractions were sonicated for 15 s using a probe sonicator before loading to
SDS-PAGE.
RNA sequencing. Total RNA is extracted from LSKs using RNeasy MicroPlus Kit
(Qiagen). Then the mRNA is enriched with the oligo(dT) magnetic beads (for
eukaryotes), and is fragmented into short fragments (about 100 bp). With random
hexamer-primer, the first strand of cDNA is synthesized, and then the second
strand is synthesized. The double-strand cDNA is purified with magnetic beads.
The ends of the double strand cDNA are repaired, and a single nucleotide A
(adenine) is added to the 3′-ends. Finally, sequencing adaptors are ligated to the
fragments. The ligation products are amplified with PCR. For quality control, RNA
and library preparation integrity are verified using Agilent 2100 BioAnalyzer sys-
tem and ABI StepOnePlus Real-Time PCR System. RNA sequencing library was
then constructed and then sequenced with Hiseq 4000.
Gene Set Enrichment Analysis (GSEA) was performed on gene sets from the
Molecular Signatures Database (MSigDB, https://www.broadinstitute.org/msigdb)
and additional gene sets curated from publications. Gene sets with FDR
q-value <0.05 were considered significantly enriched.
ChIP sequencing. Lin−Kit+ cells were fixed with 1% formaldehyde for 15min and
quenched with 0.125M glycine. Chromatin was isolated by the addition of lysis
buffer, followed by disruption with a Dounce homogenizer. Lysates were sonicated
and the DNA sheared to an average length of 300–500 bp. Genomic DNA (Input)
was prepared by treating aliquots of chromatin with RNase, proteinase K and heat
for de-crosslinking, followed by ethanol precipitation. Pellets were resuspended and
the resulting DNA was quantified on a NanoDrop spectrophotometer. An aliquot of
chromatin (10 µg, spiked-in with 200 ng of Drosophila chromatin) was precleared
with protein A agarose beads (Invitrogen). Genomic DNA regions of interest were
isolated using 4 µg of antibody against Histone H3K27me3 (clone: 39155, Active
Motif). Antibody against H2Av (0.4 µg) was also present in the reaction to ensure
efficient pull-down of the spike-in chromatin60. Complexes were washed, eluted
from the beads with SDS buffer, and subjected to RNase and proteinase K treatment.
Crosslinks were reversed by incubation overnight at 65 °C, and ChIP DNA was
purified by phenol–chloroform extraction and ethanol precipitation.
Illumina sequencing libraries were prepared from the ChIP and Input DNAs by
the standard consecutive enzymatic steps of end-polishing, dA-addition, and
adaptor ligation. After a final PCR amplification step, the resulting DNA libraries
were quantified and sequenced on Illumina’s NextSeq 500 (75 nt reads, single end).
Reads were aligned consecutively to the mouse genome (mm10) and to the
Drosophila genome (dm3) using the BWA algorithm (default settings). Duplicate
reads were removed and only uniquely mapped reads (mapping quality >= 25)
were used for further analysis. The number of mouse alignments used in the
analysis was adjusted according to the number of Drosophila alignments that were
counted in the samples that were compared. Mouse alignments were extended in
silico at their 3′-ends to a length of 200 bp, which is the average genomic fragment
length in the size-selected library, and assigned to 32-nt bins along the genome.
The resulting histograms (genomic “signal maps”) were stored in bigWig files.
H3K27me3 enriched regions were identified using the SICER algorithm with a
MaxGap parameter setting of 600 bp. Signal maps and peak locations were used as
input data to Active Motifs proprietary analysis program, which creates Excel
tables containing detailed information on sample comparison, peak metrics, peak
locations, and gene annotations.
Statistical information. Statistical analysis was performed with GraphPad Prism
8 software (GraphPad software, Inc.). All data are presented as mean ± standard
error of the mean (SEM). The sample size for each experiment and the replicate
number of experiments are included in the figure legends. Statistical analyses were
performed using Student’s t test where applicable for comparison between two
groups, and a one-way ANOVA test or two-way ANOVA was used for experi-
ments involving more than two groups. Statistical significance was defined as
*P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001; ns, not significant.
Reporting summary. Further information on research design is available in
the Nature Research Reporting Summary linked to this article.
Data availability
All RNA-seq and ChIP-seq data from this study were deposited in the Gene Expression
Omnibus (GEO) with the accession number of GSE137126. The source data underlying
all figures are provided as Source Data files. All other remaining data are available within
the article and Supplemental Files, or available from the authors upon request.
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